Clinical Trial Update: Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease [Phase 3]

View source ↗

Summary

A Phase 3 safety and efficacy trial of TRx0237 in subjects with mild to moderate Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• TRx0237

Snippet

Sponsor: TauRx Therapeutics Ltd | Conditions: Alzheimer's Disease | Phase 3 | Status: COMPLETED